
Verona Pharma’s Breakout Stood Out in a Weak Market
Patrick Dunuwila and Alfonso DePablos favored Verona’s relative strength on September 10, 2024, while separating bullish momentum from warning signs in Pennant, Check Point and Twist.
IDEAS / Tickers
The Pennant Group

Patrick Dunuwila and Alfonso DePablos favored Verona’s relative strength on September 10, 2024, while separating bullish momentum from warning signs in Pennant, Check Point and Twist.